GSK Rotarix Data Show Efficacy Against Virus Types Representing 98 Percent Of Rotavirus Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Data formed the basis of GSK’s BLA application for the rotavirus vaccine in the U.S., the company tells “The Pink Sheet” DAILY.
You may also be interested in...
FDA Panel Will Review Rotarix Pneumonia-Related Events
Agency analysis of GlaxoSmithKline rotavirus vaccine showed more pneumonia-related deaths and convulsions in clinical studies.
FDA Panel Will Review Rotarix Pneumonia-Related Events
Agency analysis of GlaxoSmithKline rotavirus vaccine showed more pneumonia-related deaths and convulsions in clinical studies.
GSK’s Rotarix Gets FDA Vaccines Advisory Committee Review
Feb. 20 meeting to focus on product safety for Rotarix, which would have a shorter dosing schedule than Merck’s RotaTeq and target more virus types.